Latent HIV-1 is activated by exosomes from cells infected with either replication-competent or defective HIV-1

Retrovirology

Volumn 12, Issue 1, 2015, Pages

  Arenaccio, Claudia ^a,b   Anticoli, Simona ^a   Manfredi, Francesco ^a   Chiozzini, Chiara ^a   Olivetta, Eleonora ^a   Federico, Maurizio ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b ROMA TRE UNIVERSITY   (Italy)

Author keywords

ADAM17; CD4+ T lymphocytes; Exosomes; HIV 1 latency; Nef

Indexed keywords

NEF PROTEIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; ADAM PROTEIN; ADAM17 PROTEIN, HUMAN; HYDROXAMIC ACID; TAPI-2; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ARTICLE; CD4+ T LYMPHOCYTE; COCULTURE; EXOSOME; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LATENT VIRUS INFECTION; NEF GENE; PRIMARY CELL; PROTEIN PURIFICATION; U937 CELL LINE; VIRUS ACTIVATION; VIRUS CULTURE; VIRUS REPLICATION; VIRUS STRAIN; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; U-937 CELL LINE; VIROLOGY; VIRUS LATENCY;

ADAM PROTEINS; ADAM17 PROTEIN; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COCULTURE TECHNIQUES; EXOSOMES; HIV-1; HUMANS; HYDROXAMIC ACIDS; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS; VIRUS ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84945259448     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-015-0216-y     Document Type: Article

References (59)

1. Siliciano RF, Greene WC. HIV latency. Cold Spring Harb Perspect Med. 2011;1(1):a007096.
2. + T cells in the absence of activating stimuli. J Virol. 2005;79(22):14179-88.
3. Siliciano JD, Siliciano RF. AIDS/HIV. Rekindled HIV infection. Science. 2014;345(6200):1005-6.
4. + T cells. Nat Med. 2003;9(6):727-8.
5. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15(8):893-900.
6. György B, Szabó TG, Pásztói M, Pál Z, Misják P, Aradi B, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci. 2011;68(16):2667-88.
7. Booth AM, Fang Y, Fallon JK, Yang JM, Hildreth JE, Gould SJ. Exosomes and HIV Gag bud from endosome-like domains of the T cell plasma membrane. Cell Biol. 2006;172(6):923-35.
8. Usami Y, Popov S, Popova E, Inoue M, Weissenhorn WG, Göttlinger H. The ESCRT pathway and HIV-1 budding. Biochem Soc Trans. 2009;37(Pt 1):181-4.
9. Fang Y, Wu N, Gan X, Yan WH, Morrell JC, Gould SJ. Higher-order oligomerization targets plasma membrane proteins and HIV gag to exosomes. PLoS Biol. 2007;5:1267-83.
10. + T cells. Traffic. 2010;11(1):110-22.
11. Muratori C, Cavallin LE, Krätzel K, Tinari A, De Milito A, Fais S, et al. Massive secretion by T cells is caused by HIV Nef in infected cells and by Nef transfer to bystander cells. Cell Host Microbe. 2009;6(3):218-30.
12. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteom. 2010;73(10):1907-20.
13. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470-6.
14. + T lymphocyte ingesting exosomes from cells expressing defective HIV-1. Retrovirology. 2014;11:46.
15. + T lymphocytes to replicate HIV-1 through a Nef- and ADAM17-dependent mechanism. J Virol. 2014;88(19):11529-39.
16. Gooz M. ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol. 2010;45:146-69.
17. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA. 1989;86(7):2365-8.
18. Rasola A, Gramaglia D, Boccaccio C, Comoglio PM. Apoptosis enhancement by the HIV-1 Nef protein. J Immunol. 2001;166(1):81-8.
19. Muthumani K, Choo AY, Shedlock DJ, Laddy DJ, Sundaram SG, Hirao L, et al. Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism. J Virol. 2008;82(23):11536-44.
20. Zauli G, Gibellini D, Secchiero P, Dutartre H, Olive D, Capitani S, et al. Human immunodeficiency virus type 1 Nef protein sensitizes CD4(+) T lymphoid cells to apoptosis via functional upregulation of the CD95/CD95 ligand pathway. Blood. 1999;93(3):1000-10.
21. Olivetta E, Pietraforte D, Schiavoni I, Minetti M, Federico M, Sanchez M. HIV-1 Nef regulates the release of superoxide anions from human macrophages. Biochem J. 2005;390(Pt 2):591-602.
22. Walk SF, Alexander M, Maier B, Hammarskjold ML, Rekosh DM, Ravichandran KS. Design and use of an inducibly activated human immunodeficiency virus type 1 Nef to study immune modulation. J Virol. 2001;75(2):834-43.
23. Rieu S, Geminard C, Rabesandratana H, Sainte-Marie J, Vidal M. Exosomes released during reticulocyte maturation bind to fibronectin via integrin alpha 4 beta 1. Eur J Biochem. 2000;267:583-90.
24. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem. 1998;273:20121-7.
25. Rabesandratana H, Toutant JP, Reggio H, Vidal M. Decay-accelerating factor (CD55) and membrane inhibitor of reactive lysis (CD59) are released within exosomes during In vitro maturation of reticulocytes. Blood. 1998;91(7):2573-80.
26. Folks TM, Justement J, Kinter A, Schnittman S, Orenstein J, Poli G, et al. Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J Immunol. 1988;140(4):1117-22.
27. Emiliani S, Fischle W, Ott M, Van Lint C, Amella CA, Verdin E. Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J Virol. 1998;72(2):1666-70.
28. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science. 1987;238(4828):800-2.
29. Lee JH, Wittki S, Brau T, Dreyer FS, Kratzel K, Dindorf J, et al. HIV Nef, paxillin, and Pak1/2 regulate activation and secretion of TACE/ADAM10 proteases. Mol Cell. 2013;49:668-79.
30. Moss ML, Rasmussen FH. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. Anal Biochem. 2007;366:144-8.
31. Lassen KG, Hebbeler AM, Bhattacharyya D, Lobritz MA, Greene WC. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS One. 2012;7(1):e30176.
32. + T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood. 2007;110:4161-4.
33. Bosque A, Planelles V. Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells. Methods. 2011;53:54-61.
34. Yang HC, Xing S, Shan L, O'Connell K, Dinoso J, Shen A, et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest. 2009;119:3473-86.
35. + T cells. AIDS. 2008;22:1131-5.
36. Spina CA, Guatelli JC, Richman DD. Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol. 1995;69:2977-88.
37. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 2003;22:1868-77.
38. + T cells from aviremic patients. PLoS Pathog. 2013;9:e1003834.
39. Chairoungdua A, Smith DL, Pochard P, Hull M, Caplan MJ. Exosome release of beta-catenin: a novel mechanism that antagonizes Wnt signaling. J Cell Biol. 2010;190:1079-91.
40. Kogure T, Lin WL, Yan IK, Braconi C, Patel T. Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology. 2011;54:1237-48.
41. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010;285:17442-52.
42. Kosaka N, Iguchi H, Yoshioka Y, Hagiwara K, Takeshita F, Ochiya T. Competitive interactions of cancer cells and normal cells via secretory microRNAs. J Biol Chem. 2012;287:1397-405.
43. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319:1244-7.
44. Yuyama K, Sun H, Mitsutake S, Igarashi Y. Sphingolipid-modulated exosome secretion promotes clearance of amyloid-beta by microglia. J Biol Chem. 2012;287:10977-89.
45. Sanchez G, Xu XY, Chermann JC, Hirsch I. Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals. J Virol. 1997;71(3):2233-40.
46. Fourati S, Lambert-Niclot S, Soulie C, Malet I, Valantin MA, Descours B, et al. HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs. J Antimicrob Chemother. 2012;67(10):2323-6.
47. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013;155(3):540-51.
48. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 2013;9(2):e1003174.
49. Janini M, Rogers M, Birx DR, McCutchan FE. Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J Virol. 2001;75:7973-86.
50. Federico M, Titti F, Butto S, Orecchia A, Carlini F, Taddeo B, et al. Biologic and molecular characterization of producer and nonproducer clones from HUT-78 cells infected with a patient HIV isolate. AIDS Res Hum Retrovir. 1989;5:385-96.
51. Kadiu I, Narayanasamy P, Dash PK, Zhang W, Gendelman HE. Biochemical and biologic characterization of exosomes and microvesicles as facilitators of HIV-1 infection in macrophages. J Immunol. 2012;189(2):744-54.
52. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L Jr, Ingerman MJ, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 1999;282(17):1627-32.
53. Fischer M, Günthard HF, Opravil M, Joos B, Huber W, Bisset LR, et al. Residual HIV-RNA levels persist for up to 2.5years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy. AIDS Res Hum Retrovir. 2000;16(12):1135-40.
54. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, et al. Low-level viremia persists for at least 7years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA. 2008;105(10):3879-84.
55. Wong JK, Hezareh M, Günthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278(5341):1291-5.
56. Federico M, Percario Z, Olivetta E, Fiorucci G, Muratori C, Micheli A, et al. HIV-1 Nef activates STAT1 in human monocytes/macrophages through the release of soluble factors. Blood. 2001;98:2752-61.
57. + T lymphocytes independently of exosomes. Virol J. 2010;7:234.
58. Cantin R, Diou J, Belanger D, Tremblay AM, Gilbert C. Discrimination between exosomes and HIV-1: purification of both vesicles from cell-free supernatants. J Immunol Methods. 2008;338:21-30.
59. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006;3(3):22.